Harvard Bioscience (HBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 8,614 | 4,108 | 4,283 | 4,508 | 7,821 |
| Receivables | 16,043 | 14,866 | 16,099 | 16,705 | 21,834 |
| Inventories | 20,805 | 23,245 | 24,716 | 26,439 | 27,587 |
| Other current assets | 2,763 | 2,898 | 3,940 | 3,472 | 4,341 |
| TOTAL | $48,225 | $45,117 | $49,038 | $51,124 | $61,583 |
| Non-Current Assets | |||||
| PPE Net | 4,787 | 5,106 | 3,981 | 3,366 | 3,415 |
| Intangibles | 17,198 | 67,456 | 73,101 | 77,274 | 85,074 |
| Other Non-Current Assets | 9,861 | 8,965 | 11,246 | 13,596 | 12,272 |
| TOTAL | $31,846 | $81,527 | $88,328 | $94,236 | $100,761 |
| Total Assets | $80,071 | $126,644 | $137,366 | $145,360 | $162,344 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 36,956 | 5,859 | 3,811 | 3,235 |
| Accounts payable and accrued liabilities | 3,652 | 4,787 | 5,554 | 6,447 | 4,911 |
| Other current liabilities | 18,308 | 13,215 | 15,129 | 10,856 | 10,762 |
| TOTAL | $21,960 | $54,958 | $26,542 | $23,249 | $25,316 |
| Non-Current Liabilities | |||||
| Long Term Debt | 35,870 | N/A | 30,704 | 43,013 | 45,095 |
| Deferred Revenues | N/A | N/A | N/A | N/A | 4,266 |
| Other Non-Current Liabilities | 8,190 | 7,636 | 6,270 | 6,288 | 6,974 |
| TOTAL | $44,377 | $8,346 | $37,750 | $49,891 | $53,627 |
| Total Liabilities | $66,337 | $63,304 | $64,292 | $73,140 | $78,943 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 4,472 | 4,407 | 4,340 | 4,219 | 4,123 |
| Common Shares | 447 | 441 | 434 | 454 | 452 |
| Retained earnings | -214,710 | -158,010 | -145,605 | -142,190 | -132,674 |
| Other shareholders' equity | -11,672 | -15,670 | -14,190 | -15,052 | -10,027 |
| TOTAL | $13,734 | $63,340 | $73,074 | $72,220 | $83,401 |
| Total Liabilities And Equity | $80,071 | $126,644 | $137,366 | $145,360 | $162,344 |